or Try an Advanced Search...

    Tyrosine Kinase Stocks List

    Symbol Grade Name % Change
    RLAY F Relay Therapeutics, Inc. -0.43
    ALLR F Allarity Therapeutics, Inc. 5.88
    NVCT F Nuvectis Pharma, Inc. -3.35
    BBIO F BridgeBio Pharma, Inc. 0.87
    KRON D Kronos Bio, Inc. 1.66
    EYPT D EyePoint Pharmaceuticals, Inc. -6.76
    COGT D Cogent Biosciences, Inc. -1.10
    KALA C Kala Pharmaceuticals, Inc. 1.87
    PBYI C Puma Biotechnology Inc 2.11
    AVBP C ArriVent BioPharma, Inc. -2.99
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Protein Kinase Inhibitor Biopharmaceutical Enzymes Solid Tumors Tyrosine Kinase Receptors Biology Biotechnology Eye Fibroblast Growth Factor Receptor Glucocorticoids Inflammation Macular Degeneration Medicine Non Small Cell Lung Cancer Ophthalmic Organ Systems Organic Compounds Proto Oncogene Tyrosine Protein Kinase Src Treatment Of Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Tyrosine Kinase stocks.

    Symbol Grade Name Weight
    HRTS F Tema Cardiovascular and Metabolic ETF 3.69
    CANC D Tema Oncology ETF 1.64
    WDNA D WisdomTree BioRevolution Fund 1.59
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 1.43
    BBP C BioShares Biotechnology Products Fund 1.19
    View all Tyrosine Kinase ETFs...
    Compare ETFs
    Compare CANC to BBP Compare HRTS to WDNA Compare WDNA to BBC

        Tyrosine Kinase Stocks Recent News

        Date Stock Title
        Nov 21 BBIO Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
        Nov 21 PBYI PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
        Nov 21 PBYI Puma commences Phase II trial of alisertib for breast cancer treatment
        Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 20 PBYI Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
        Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
        Nov 19 RLAY Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
        Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
        Nov 18 ALLR Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
        Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
        Nov 17 KRON Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
        Nov 16 KRON Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
        Nov 15 NVCT Nuvectis Pharma reports data from Phase 1b study of NXP800
        Nov 15 AVBP ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Protein Kinase Inhibitor Biopharmaceutical Enzymes Solid Tumors Tyrosine Kinase Receptors Biology Biotechnology Eye Fibroblast Growth Factor Receptor Glucocorticoids Inflammation Macular Degeneration Medicine Non Small Cell Lung Cancer Ophthalmic Organ Systems Organic Compounds Proto Oncogene Tyrosine Protein Kinase Src Treatment Of Cancer
        Tyrosine Kinase

        Tyrosine kinase is an enzyme that catalyzes the transfer of phosphate groups from ATP to tyrosine residues on proteins. It is involved in many cellular processes, including cell growth, differentiation, and migration. Tyrosine kinases are also involved in signal transduction pathways, which are important for cell communication and regulation. Mutations in tyrosine kinases can lead to cancer and other diseases.

        Browse All Tags